Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (5): 460-465.DOI: 10.3969/j.issn.1673-8640.2023.05.010
Previous Articles Next Articles
LIANG Chaohui, ZHAO Fan, LIU Qianwen
Received:
2021-07-29
Revised:
2022-10-13
Online:
2023-05-30
Published:
2023-08-07
CLC Number:
LIANG Chaohui, ZHAO Fan, LIU Qianwen. Relationship between macrophage migration inhibitory factor and carotid vascular calcification in elderly patients with type 2 diabetes mellitus[J]. Laboratory Medicine, 2023, 38(5): 460-465.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.05.010
项目 | 例数 | 性别 | 年龄/岁 | BMI/ (kg/m2) | 糖尿病病程/年 | 吸烟史/ [例(%)] | |
---|---|---|---|---|---|---|---|
男 | 女 | ||||||
无钙化组 | 41 | 21 | 20 | 66.84±4.36 | 21.96±1.54 | 5.41±2.68 | 12(29.27) |
低钙化组 | 67 | 40 | 27 | 68.02±4.58 | 22.31±1.48 | 7.24±3.85# | 22(32.84) |
高钙化组 | 56 | 33 | 23 | 67.04±4.68 | 22.42±1.58 | 9.38±4.51#* | 21(37.50) |
统计值 | 0.838 | 1.143 | 0.850 | 12.881 | 0.745 | ||
P值 | 0.658 | 0.321 | 0.429 | <0.001 | 0.689 | ||
项目 | 收缩压/ kPa | 舒张压/ kPa | TC/ (mmol/L) | TG/ (mmol/L) | LDL-C/ (mmol/L) | 肌酐/ (μmmol/L) | |
无钙化组 | 18.12±2.81 | 11.99±3.27 | 4.37±0.84 | 1.58±0.63 | 2.34±0.68 | 81.31±12.15 | |
低钙化组 | 19.41±3.01# | 12.41±3.68 | 4.78±0.93# | 1.92±0.75# | 2.72±0.82# | 84.91±13.64 | |
高钙化组 | 19.78±3.42# | 12.54±3.91 | 5.21±1.06#* | 1.98±0.83# | 3.04±0.86#* | 86.94±14.18 | |
统计值 | 9.443 | 2.673 | 9.261 | 3.772 | 9.034 | 2.064 | |
P值 | <0.001 | 0.152 | <0.001 | 0.025 | <0.001 | 0.130 | |
项目 | 尿素/ (mmol/L) | AST/ (U/L) | ALT/ (U/L) | 空腹血糖/(mmol/L) | hs-CRP/ (mg/L) | MIF/ (ng/mL) | |
无钙化组 | 5.56±1.41 | 21.64±10.31 | 22.93±9.69 | 8.53±0.84 | 1.25±0.68 | 21.69±5.89 | |
低钙化组 | 5.67±1.52 | 24.81±13.56 | 26.48±14.33 | 9.18±0.96# | 1.73±0.92# | 29.48±8.54# | |
高钙化组 | 5.84±1.61 | 25.87±14.31 | 27.26±15.08 | 9.32±1.05# | 2.38±1.03#* | 36.87±10.59#* | |
统计值 | 0.422 | 1.331 | 1.358 | 8.746 | 19.048 | 35.802 | |
P值 | 0.657 | 0.267 | 0.260 | <0.001 | <0.001 | <0.001 |
项目 | 例数 | 性别 | 年龄/岁 | BMI/ (kg/m2) | 糖尿病病程/年 | 吸烟史/ [例(%)] | |
---|---|---|---|---|---|---|---|
男 | 女 | ||||||
无钙化组 | 41 | 21 | 20 | 66.84±4.36 | 21.96±1.54 | 5.41±2.68 | 12(29.27) |
低钙化组 | 67 | 40 | 27 | 68.02±4.58 | 22.31±1.48 | 7.24±3.85# | 22(32.84) |
高钙化组 | 56 | 33 | 23 | 67.04±4.68 | 22.42±1.58 | 9.38±4.51#* | 21(37.50) |
统计值 | 0.838 | 1.143 | 0.850 | 12.881 | 0.745 | ||
P值 | 0.658 | 0.321 | 0.429 | <0.001 | 0.689 | ||
项目 | 收缩压/ kPa | 舒张压/ kPa | TC/ (mmol/L) | TG/ (mmol/L) | LDL-C/ (mmol/L) | 肌酐/ (μmmol/L) | |
无钙化组 | 18.12±2.81 | 11.99±3.27 | 4.37±0.84 | 1.58±0.63 | 2.34±0.68 | 81.31±12.15 | |
低钙化组 | 19.41±3.01# | 12.41±3.68 | 4.78±0.93# | 1.92±0.75# | 2.72±0.82# | 84.91±13.64 | |
高钙化组 | 19.78±3.42# | 12.54±3.91 | 5.21±1.06#* | 1.98±0.83# | 3.04±0.86#* | 86.94±14.18 | |
统计值 | 9.443 | 2.673 | 9.261 | 3.772 | 9.034 | 2.064 | |
P值 | <0.001 | 0.152 | <0.001 | 0.025 | <0.001 | 0.130 | |
项目 | 尿素/ (mmol/L) | AST/ (U/L) | ALT/ (U/L) | 空腹血糖/(mmol/L) | hs-CRP/ (mg/L) | MIF/ (ng/mL) | |
无钙化组 | 5.56±1.41 | 21.64±10.31 | 22.93±9.69 | 8.53±0.84 | 1.25±0.68 | 21.69±5.89 | |
低钙化组 | 5.67±1.52 | 24.81±13.56 | 26.48±14.33 | 9.18±0.96# | 1.73±0.92# | 29.48±8.54# | |
高钙化组 | 5.84±1.61 | 25.87±14.31 | 27.26±15.08 | 9.32±1.05# | 2.38±1.03#* | 36.87±10.59#* | |
统计值 | 0.422 | 1.331 | 1.358 | 8.746 | 19.048 | 35.802 | |
P值 | 0.657 | 0.267 | 0.260 | <0.001 | <0.001 | <0.001 |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
糖尿病病程 | 1.245 | 0.297 | 17.572 | 0.000 | 3.473(1.940~6.216) |
TC | 0.731 | 0.289 | 6.398 | 0.011 | 2.077(1.179~3.660) |
LDL-C | 0.802 | 0.373 | 4.623 | 0.032 | 2.230(1.074~4.632) |
hs-CRP | 0.948 | 0.305 | 9.661 | 0.002 | 2.581(1.419~4.692) |
MIF | 1.154 | 0.408 | 8.000 | 0.005 | 3.171(1.425~7.055) |
收缩压 | 0.907 | 0.263 | 1.925 | 0.257 | 1.478(0.637~5.653) |
空腹血糖 | 1.020 | 0.201 | 2.728 | 0.106 | 1.774(0.816~4.769) |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
糖尿病病程 | 1.245 | 0.297 | 17.572 | 0.000 | 3.473(1.940~6.216) |
TC | 0.731 | 0.289 | 6.398 | 0.011 | 2.077(1.179~3.660) |
LDL-C | 0.802 | 0.373 | 4.623 | 0.032 | 2.230(1.074~4.632) |
hs-CRP | 0.948 | 0.305 | 9.661 | 0.002 | 2.581(1.419~4.692) |
MIF | 1.154 | 0.408 | 8.000 | 0.005 | 3.171(1.425~7.055) |
收缩压 | 0.907 | 0.263 | 1.925 | 0.257 | 1.478(0.637~5.653) |
空腹血糖 | 1.020 | 0.201 | 2.728 | 0.106 | 1.774(0.816~4.769) |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | P值 | 约登指数 |
---|---|---|---|---|---|---|
MIF | 0.881(0.726~0.985) | 30.80 ng/mL | 75.61 | 92.68 | 0.003 | 0.683 |
hs-CRP | 0.823(0.623~0.854) | 1.75 mg/L | 74.91 | 82.94 | 0.019 | 0.642 |
LDL-C | 0.735(0.709~0.881) | 2.71 mmol/L | 68.39 | 85.27 | 0.035 | 0.537 |
TC | 0.561(0.494~0.762) | 4.76 mmol/L | 71.33 | 89.62 | 0.015 | 0.610 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | P值 | 约登指数 |
---|---|---|---|---|---|---|
MIF | 0.881(0.726~0.985) | 30.80 ng/mL | 75.61 | 92.68 | 0.003 | 0.683 |
hs-CRP | 0.823(0.623~0.854) | 1.75 mg/L | 74.91 | 82.94 | 0.019 | 0.642 |
LDL-C | 0.735(0.709~0.881) | 2.71 mmol/L | 68.39 | 85.27 | 0.035 | 0.537 |
TC | 0.561(0.494~0.762) | 4.76 mmol/L | 71.33 | 89.62 | 0.015 | 0.610 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | ||
性别 | 0.543(0.217~1.336) | 0.371 | |||
年龄 | 0.556(0.148~1.672) | 0.508 | |||
BMI | 1.845(0.330~2.471) | 0.112 | |||
糖尿病病程 | 0.436(0.351~1.594) | 0.628 | |||
吸烟史 | 0.628(0.533~1.894) | 0.431 | |||
收缩压 | 0.722(0.618~1.937) | 0.294 | |||
舒张压 | 0.207(0.129~1.583) | 0.136 | |||
TG | 2.433(2.210~3.875) | 0.002 | |||
肌酐 | 1.631(1.293~3.628) | 0.007 | |||
尿素 | 1.447(1.152~1.893) | 0.011 | 0.430(0.279~2.883) | 0.190 | |
AST | 1.593(1.288~1.904) | 0.022 | 2.367(0.401~2.955) | 0.128 | |
ALT | 1.461(1.179~2.004) | 0.011 | 2.074(0.643~2.585) | 0.154 | |
空腹血糖 | 3.401(2.148~5.830) | 0.009 | 1.226(0.851~3.739) | 0.173 | |
TC | 2.326(1.138~3.527) | 0.037 | 2.531(0.646~2.827) | 0.084 | |
hs-CRP | 2.605(1.594~3.622) | 0.016 | 3.091(1.628~3.862) | <0.001 | |
LDL-C | 3.068(2.915~3.673) | 0.009 | 3.597(3.174~4.928) | <0.001 | |
MIF | 4.572(2.708~5.291) | <0.001 | 3.311(2.497~3.653) | <0.001 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR(95%CI) | P值 | HR(95%CI) | P值 | ||
性别 | 0.543(0.217~1.336) | 0.371 | |||
年龄 | 0.556(0.148~1.672) | 0.508 | |||
BMI | 1.845(0.330~2.471) | 0.112 | |||
糖尿病病程 | 0.436(0.351~1.594) | 0.628 | |||
吸烟史 | 0.628(0.533~1.894) | 0.431 | |||
收缩压 | 0.722(0.618~1.937) | 0.294 | |||
舒张压 | 0.207(0.129~1.583) | 0.136 | |||
TG | 2.433(2.210~3.875) | 0.002 | |||
肌酐 | 1.631(1.293~3.628) | 0.007 | |||
尿素 | 1.447(1.152~1.893) | 0.011 | 0.430(0.279~2.883) | 0.190 | |
AST | 1.593(1.288~1.904) | 0.022 | 2.367(0.401~2.955) | 0.128 | |
ALT | 1.461(1.179~2.004) | 0.011 | 2.074(0.643~2.585) | 0.154 | |
空腹血糖 | 3.401(2.148~5.830) | 0.009 | 1.226(0.851~3.739) | 0.173 | |
TC | 2.326(1.138~3.527) | 0.037 | 2.531(0.646~2.827) | 0.084 | |
hs-CRP | 2.605(1.594~3.622) | 0.016 | 3.091(1.628~3.862) | <0.001 | |
LDL-C | 3.068(2.915~3.673) | 0.009 | 3.597(3.174~4.928) | <0.001 | |
MIF | 4.572(2.708~5.291) | <0.001 | 3.311(2.497~3.653) | <0.001 |
[1] |
TAY H M, LEONG S Y, XU X, et al. Direct isolation of circulating extracellular vesicles from blood for vascular risk profiling in type 2 diabetes mellitus[J]. Lab Chip, 2021, 21(13):2511-2523.
DOI PMID |
[2] |
WU C Y, MARTEL J, YOUNG J D. Ectopic calcification and formation of mineralo-organic particles in arteries of diabetic subjects[J]. Sci Rep, 2020, 10(1):8545.
DOI |
[3] | 杨晶, 赵衡, 刘江华. 内皮细胞在血管钙化进程中的作用[J]. 临床与病理杂志, 2020, 40(1):130-135. |
[4] |
QIAO C, LI S, LU H, et al. Laminar flow attenuates macrophage migration inhibitory factor expression in endothelial cells[J]. Sci Rep, 2018, 8(1):2360.
DOI PMID |
[5] | 杜雪霞, 陈宝峰, 邓芸, 等. 巨噬细胞移动抑制因子与2型糖尿病合并大血管病的关系研究[J]. 疑难病杂志, 2015, 14(1):29-32. |
[6] | 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4):292-344. |
[7] | 耿跃, 杜睿, 赵江波, 等. 糖尿病患者血清Nε-羧甲基赖氨酸水平与颈动脉钙化关系的临床研究[J]. 中国动脉硬化杂志, 2020, 28(4):316-321. |
[8] |
OUYANG L, ZHANG K, CHEN J, et al. Roles of platelet-derived growth factor in vascular calcification[J]. J Cell Physiol, 2018, 233(4):2804-2814.
DOI PMID |
[9] |
YAHAGI K, KOLODGIE F D, LUTTER C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus[J]. Arterioscler Thromb Vasc Biol, 2017, 37(2):191-204.
DOI PMID |
[10] | 孙学娇, 刘乃丰. 关注糖尿病与血管钙化的共同发病机制和临床意义[J]. 中国动脉硬化杂志, 2020, 28(2):169-174. |
[11] |
KOIKE S, YANO S, TANAKA S, et al. Advanced glycation end-products induce apoptosis of vascular smooth muscle cells:a mechanism for vascular calcification[J]. Int J Mol Sci, 2016, 17(9):1567.
DOI URL |
[12] |
GUO J, ERQOU S A, MILLER R G, et al. The role of coronary artery calcification testing in incident coronary artery disease risk prediction in type 1 diabetes[J]. Diabetologia, 2019, 62(2):259-268.
DOI PMID |
[13] | 郑晓茂, 茹琴, 陈琳, 等. 晚期糖基化终产物对糖尿病及其并发症的影响和干预的研究进展[J]. 重庆医学, 2019, 48(13):2292-2296. |
[14] | 邓湘宁, 王新宇, 高炜. 巨噬细胞移动抑制因子——心肌缺血/再灌注损伤的诊疗新靶点[J]. 中国介入心脏病学杂志, 2019, 27(8):470-473. |
[15] | 王征, 伍成文, 陈豪, 等. 二肽基肽酶-Ⅳ抑制剂通过激活ERK1/2和NF-κB信号通路促进2型糖尿病小鼠主动脉血管钙化[J]. 转化医学杂志, 2019, 8(3):144-148. |
[16] | 陈秀鹃, 孙琳, 张正军, 等. 长链非编码RNA-ANCR对小鼠血管平滑肌细胞成骨样分化的影响[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017, 10(3):252-259. |
[17] | 王征, 伍成文, 陈豪, 等. 二肽基肽酶-Ⅳ抑制剂通过激活ERK1/2和NF-κB信号通路促进2型糖尿病小鼠主动脉血管钙化[J]. 转化医学杂志, 2019, 8(3):144-148. |
[18] | 曾忠华, 蔡林, 雷鹏程. 巨噬细胞移动抑制因子过表达对成骨细胞骨形态蛋白-2和血管内皮生长因子表达的影响[J]. 中华实验外科杂志, 2012, 29(1):3. |
[19] | 王志刚, 魏萌, 王萌, 等. 巨噬细胞迁移抑制因子对2型糖尿病小鼠肾脏损害的影响[J]. 实用老年医学, 2020, 34(9):894-898. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||